Jeffrey Thomas Elliott Exact Sciences Corp (EXAS) insider trading activity

Jeffrey Thomas Elliott is Chief Financial Officer of EXACT SCIENCES CORP. Currently has a direct ownership of 11,795 shares of EXAS, which is worth approximately $625,960. The most recent transaction as insider was on May 01, 2024, when has been sold 136 shares (Common Stock) at a price of $60.15 per share, resulting in proceeds of $8,180. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 11.8K

0% 3M change

Infinity% 12M change

Total Value Held $625,960

Jeffrey Thomas Elliott Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 01 2024	SELL Open market or private sale	$8,180 $60.15 p/Share	136 Reduced 1.14%	11,795 Common Stock
Apr 30 2024	BUY Grant, award, or other acquisition	$14,979 $15.01 p/Share	998 Added 7.72%	11,931 Common Stock
Mar 01 2024	SELL Open market or private sale	$143,079 $59.32 p/Share	2,412 Reduced 18.07%	10,933 Common Stock
Feb 29 2024	BUY Exercise of conversion of derivative security	-	5,291 Added 28.39%	13,345 Common Stock
Feb 27 2024	SELL Open market or private sale	$154,171 $56.89 p/Share	2,710 Reduced 25.18%	8,054 Common Stock
Feb 26 2024	BUY Exercise of conversion of derivative security	-	5,701 Added 34.62%	10,764 Common Stock
Feb 22 2024	SELL Open market or private sale	$80,762 $59.78 p/Share	1,351 Reduced 21.06%	5,063 Common Stock
Feb 21 2024	SELL Open market or private sale	$91,819 $61.5 p/Share	1,493 Reduced 28.73%	3,703 Common Stock
Feb 21 2024	BUY Grant, award, or other acquisition	-	2,711 Added 29.71%	6,414 Common Stock
Feb 20 2024	BUY Exercise of conversion of derivative security	-	3,112 Added 37.46%	5,196 Common Stock
Feb 15 2024	SELL Open market or private sale	$115,979 $61.43 p/Share	1,888 Reduced 47.53%	2,084 Common Stock
Feb 14 2024	BUY Exercise of conversion of derivative security	-	3,972 Added 50.0%	3,972 Common Stock
Aug 21 2023	SELL Open market or private sale	$2,505,013 $82.92 p/Share	30,210 Reduced 100.0%	0 Common Stock
May 01 2023	BUY Grant, award, or other acquisition	$21,284 $30.02 p/Share	709 Added 2.29%	30,210 Common Stock
Feb 28 2023	SELL Open market or private sale	$258,720 $61.12 p/Share	4,233 Reduced 12.65%	29,241 Common Stock
Feb 27 2023	BUY Exercise of conversion of derivative security	-	9,137 Added 21.44%	33,474 Common Stock
Feb 22 2023	SELL Open market or private sale	$89,689 $62.72 p/Share	1,430 Reduced 5.55%	24,337 Common Stock
Feb 21 2023	BUY Exercise of conversion of derivative security	-	3,112 Added 10.78%	25,767 Common Stock
Feb 15 2023	SELL Open market or private sale	$122,390 $65.59 p/Share	1,866 Reduced 7.61%	22,655 Common Stock
Feb 14 2023	BUY Exercise of conversion of derivative security	-	3,972 Added 13.94%	24,521 Common Stock
Feb 13 2023	SELL Open market or private sale	$74,748 $64.55 p/Share	1,158 Reduced 5.33%	20,549 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	-	2,579 Added 10.62%	21,707 Common Stock
May 02 2022	BUY Grant, award, or other acquisition	$12,326 $47.41 p/Share	260 Added 0.87%	29,501 Common Stock
Mar 01 2022	SELL Open market or private sale	$310,595 $76.69 p/Share	4,050 Reduced 17.47%	19,128 Common Stock
Feb 28 2022	BUY Exercise of conversion of derivative security	-	8,462 Added 26.74%	23,178 Common Stock

Also insider at

QTRX

Quanterix Corp Healthcare

JTE